Belimumab treatment for adults with systemic lupus erythematosus a review of clinical effectiveness, cost-effectiveness, and guidelines
Systemic lupus erythematosus (SLE) is a chronic, remitting autoimmune disease related to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee did not recommend listing belimumab in public drug formularies in 2012. The recommendation was based...
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, May 23, 2018
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Systemic lupus erythematosus (SLE) is a chronic, remitting autoimmune disease related to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee did not recommend listing belimumab in public drug formularies in 2012. The recommendation was based on two major randomized controlled trials. Recently, new trials examining belimumab have been published and it is unclear whether the latest evidence would support or change the 2012 Centre for Reviews and Dissemination (CDR) recommendation. The objective of this report is to review the latest evidence in order to further determine the clinical and cost-effectiveness of belimumab for the treatment of systemic lupus erythematosus (SLE), as well as to review the evidence-based guidelines |
|---|---|
| Physical Description: | 1 PDF file (30 pages) |